Shopping Cart
- Remove All
- Your shopping cart is currently empty
Samalizumab (ALXN 6000) is a humanized anti-CD200 monoclonal antibody that specifically targets the CD200 immunoregulatory cell surface protein, a member of the immunoglobulin superfamily which functions to dampen excessive immune responses and maintain self-tolerance, thereby establishing Samalizumab as an effective immune checkpoint inhibitor currently under investigation for the treatment of myeloma and B-cell chronic lymphocytic leukemia (CLL).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $247 | In Stock | |
5 mg | $647 | In Stock | |
10 mg | $1,200 | In Stock |
Description | Samalizumab (ALXN 6000) is a humanized anti-CD200 monoclonal antibody that specifically targets the CD200 immunoregulatory cell surface protein, a member of the immunoglobulin superfamily which functions to dampen excessive immune responses and maintain self-tolerance, thereby establishing Samalizumab as an effective immune checkpoint inhibitor currently under investigation for the treatment of myeloma and B-cell chronic lymphocytic leukemia (CLL). |
In vitro | Samalizumab can specifically bind to the immune checkpoint CD200, block receptor binding and signal transduction, and antagonize CD200-driven immunosuppression, thereby mediating anti-tumor immune responses [1]. |
Synonyms | ALXN 6000 |
Cas No. | 1073059-33-2 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.